GLP1R and diabetes mellitus: GLP-1 receptor agonists, recognized for their efficacy in managing type 2 diabetes mellitus, include FDA-approved drugs like exenatide, liraglutide, and semaglutide, and are particularly valued for their potential to reduce cardiovascular risk, a leading cause of mortality in these patients.